



An update on physical activity in type 2 diabetes: is it all about weight loss?

Prof Jason Gill
University of Glasgow











Aerobic exercise and weight loss in adults: dose-response meta-analysis

Weight



Waist



Long term effects of diet and/or exercise on weight loss: network meta-analysis

	Diet vs Exercise
Body weight (kg)	-2.93 (-4.18, -1.68)
Waist circumference (cm)	-1.75 (-4.12, 0.62)
Fat mass (kg)	-2.20 (-3.75, -0.66)
Waist-to-hip ratio	-0.00 (-0.01, 0.01)
Total cholesterol (mg/dl)	-3.91 (-8.11, 0.30)
LDL cholesterol (mg/dl)	-3.19 (-6.85, 0.48)
HDL cholesterol (mg/dl)	-0.96 (-1.88, -0.04)
Triglyceride (mg/dl)	-3.80 (-12.21, 4.62)
Diastolic BP (mmHg)	-1.33 (-3.00, 0.35)
Systolic BP (mmHg)	-2.19 (-4.23, -0.15)
VO ₂ max (ml/kg/min)	-1.16 (-2.42, 0.09)

Studies at least 12 months in duration, values mean difference (95% CI)

Schwingshackl et al (2014) Syst Rev, 3:130

Long term effects of diet and/or exercise on weight loss: network meta-analysis

	Diet vs Exercise	Diet & Exercise vs Diet
Body weight (kg)	-2.93 (-4.18, -1.68)	-1.38 (-1.98, -0.79)
Waist circumference (cm)	-1.75 (-4.12, 0.62)	-1.68 (-2.66, -0.70)
Fat mass (kg)	-2.20 (-3.75, -0.66)	-1.65 (-2.81, -0.49)
Waist-to-hip ratio	-0.00 (-0.01, 0.01)	-0.01 (-0.02, -0.01)
Total cholesterol (mg/dl)	-3.91 (-8.11, 0.30)	-2.19 (-7.84, 3.46)
LDL cholesterol (mg/dl)	-3.19 (-6.85, 0.48)	-0.93 (-6.14, 4.27)
HDL cholesterol (mg/dl)	-0.96 (-1.88, -0.04)	1.62 (0.28, 2.95)
Triglyceride (mg/dl)	-3.80 (-12.21, 4.62)	-10.08 (-17.38, -2.79)
Diastolic BP (mmHg)	-1.33 (-3.00, 0.35)	-1.20 (-2.26, -0.15)
Systolic BP (mmHg)	-2.19 (-4.23, -0.15)	-0.24 (-1.45, 0.97)
VO ₂ max (ml/kg/min)	-1.16 (-2.42, 0.09)	3.61 (2.07, 5.14)

Studies at least 12 months in duration, values mean difference (95% CI)

Schwingshackl et al (2014) Syst Rev, 3:130

Physical activity and long-term weight maintenance





FIGURE 2. Mean ($\pm$ SEM) weight change over time by treatment group (●, standard behavior therapy group; □, high physical activity treatment group). **Significantly different from the HPA treatment group (SAS GLM procedure): * $P = 0.07$, ** $P = 0.04$.



Effects of exercise training, without weight loss, on body fat



Lee et al (2005) J Appl Physiol 99:1220-1225


60 min moderate exercise, 5 x per week for 13 weeks

Exercise and visceral fat in type 2 diabetes: systematic review and meta-analysis


Aerobic
exercise

Resistance
exercise

Combined
exercise



Exercise and liver fat in type 2 diabetes: systematic review and meta-analysis



Exercise training and intrahepatic TG in NAFLD: systematic review and meta-analysis

No significant weight loss

Significant weight loss




Figure 3 Meta-analysis of the pooled effect of exercise training on IHTG from pre-training to post-training in all exercise groups of all eligible studies when studies are grouped into those that elicited weight loss versus those that did not. IHTG, intrahepatic triglyceride; 95% CI, 95% confidence interval.


Sargeant et al (2018) Obesity Reviews 43:195-210



**Is the relationship between
physical activity and
adiposity the same in
everyone?**


Physical activity, genetic predisposition to obesity and BMI in UK Biobank

High genetic
obesity risk
(top 25%)




~4.2 kg heavier

Low genetic
obesity risk
(bottom 25%)



Physical activity, genetic predisposition to obesity and BMI in UK Biobank






Benefits of being more physically active on body weight are greater in those with high genetic risk of obesity




Key messages

Physical activity and weight loss

- Physical activity intervention alone has modest effects on bodyweight
- Effects of physical activity plus diet on bodyweight are greater than the effects of diet alone
- Even without weight loss, physical activity can substantially reduce body fat, visceral and liver fat – the scales don't tell the full story
- Effects of physical activity on body weight are greater in those with high genetic predisposition to obesity



Contraction and insulin mediated glucose uptake



Effects of prior exercise on insulin-stimulated glucose uptake across the leg





Figure 2 Exercise-improved insulin sensitivity of glucose uptake in human muscle. Prior one-legged exercise enhances sensitivity of glucose uptake to insulin in the exercised compared with the rested leg, in healthy human subjects as indicated by the decreased insulin concentration eliciting a half maximal glucose uptake response, when glucose uptake is given as percentage of maximal increase. The figure is reproduced from Wojtaszewski *et al.* (2002c) with permission. Data are extracted from Richter *et al.* (1989) and represent mean $\pm$ SE for $n = 6$.

Effects of prior exercise on insulin-stimulated glucose uptake across the leg




Acute effect:

- Present for ~48-72 hours
- Enhanced by exercise training


Figure 2 Exercise-improved insulin sensitivity of glucose uptake in human muscle. Prior one-legged exercise enhances sensitivity of glucose uptake to insulin in the exercised compared with the rested leg, in healthy human subjects as indicated by the decreased insulin concentration eliciting a half maximal glucose uptake response, when glucose uptake is given as percentage of maximal increase. The figure is reproduced from Wojtaszewski *et al.* (2002c) with permission. Data are extracted from Richter *et al.* (1989) and represent mean $\pm$ SE for $n = 6$.

Effects of supervised exercise training on glycaemic control in T2D: a meta-regression



Covariates	Coefficient	95% CI	<i>p</i>	Adjusted <i>R</i> ²
Supervised aerobic training ^b				
Intensity (% HR _{max}), <i>n</i> =13	-0.003	-0.07, 0.058	0.9	NS
Frequency (sessions/week), <i>n</i> =20	-0.69	-1.03, -0.35	<0.001	62.3%
Weekly volume (min/week), <i>n</i> =20	-0.007	-0.014, 0.0005	0.07	NS

Aerobic training, resistance training or both on glycaemic control in type 2 diabetes



- Control group (n = 41) – no exercise
- Aerobic training group (n = 72) – 12 kcal/kg/week aerobic exercise over 3 sessions/week
- Resistance training group (n = 73) – 2-3 sets of 9 resistance exercises 3 x per week
- Combined training group (n = 76) – 12 kcal/kg/week aerobic exercise over 3 sessions/week PLUS 1 set of 9 resistance exercises in each session

SIMILAR EXERCISE TIME FOR THE 3 INTERVENTION GROUPS (~130-150 MIN/WEEK)

Comparison of different exercise types in patients with T2D: systematic review and network metaanalysis


Nutrition, Metabolism & Cardiovascular Diseases (2021) 31, 1985–1992



Available online at www.sciencedirect.com

Nutrition, Metabolism & Cardiovascular Diseases

journal homepage: www.elsevier.com/locate/nmcd



SYSTEMATIC REVIEWS AND META-ANALYSES

Comparison between different types of exercise training in patients with type 2 diabetes mellitus: A systematic review and network metaanalysis of randomized controlled trials


Edoardo Mannucci^{a,b}, Allegra Bonifazi^b, Matteo Monami^a

^a Diabetology, Careggi Hospital, Florence, Italy

^b University of Florence, Italy



A



Consistency H: 1.00

ACSM/ADA recommendations for Physical activity in treatment of type 2 diabetes


- Persons with type 2 diabetes should undertake at least 150 min/week of moderate to vigorous aerobic exercise spread out during at least 3 days during the week, with no more than 2 consecutive days between bouts of aerobic activity.
- In addition to aerobic training, persons with type 2 diabetes should undertake moderate to vigorous resistance training at least 2–3 days/week.
- Supervised and combined aerobic and resistance training may confer additional health benefits, although milder forms of PA (such as yoga) have shown mixed results. Persons with type 2 diabetes are encouraged to increase their total daily unstructured PA. Flexibility training may be included but should not be undertaken in place of other recommended types of PA.




Key messages



Physical activity and glycaemic control

- Exercise acutely improves insulin sensitivity for 48-72 hours
- Frequency of physical activity is more important than intensity or volume for effects on HbA1c in patients with type 2 diabetes
- A combination of aerobic and resistance exercise is more effective for HbA1c reduction in patients type 2 diabetes than either type of exercise alone






Fitness and risk of CVD mortality in patients with type 2 diabetes



Church et al (2005) Arch Intern Med, 165:2114-2120

Kokkinos et al (2009) Diabetes Care, 32:623-628

Grip strength and risk of CVD and all-cause mortality in people with and without T2D





University
of Glasgow


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

The Look AHEAD Research Group*


Long-term effects of lifestyle intervention on CVD events in type 2 diabetes: the Look AHEAD trial



The Look AHEAD Research Group (2013) NEJM, 369(2):145-54




Morbidity and mortality after lifestyle intervention in people with IGT: The Da Qing Study 30-year follow-up






Morbidity and mortality after lifestyle intervention in people with IGT: The Da Qing Study 30-year follow-up



	Median delay, years (95% CI)	Mean number of event-free years (95% CI)	Number needed to treat (95% CI)
Diabetes	3.56 (0.25 to 6.87; p=0.0047)	4.07 (1.46 to 6.68; p=0.0022)	10 (7 to 23)
CVD events	4.64 (1.05 to 8.22; p=0.011)	1.77 (0.18 to 3.36; p=0.029)	9 (5 to 36)
Composite microvascular disease outcome	5.17 (-0.56 to 10.90; p=0.077)	0.96 (-0.12 to 2.03; p=0.080)	10 (5 to 193)
CVD deaths	7.25 (-0.18 to 14.67; p=0.056)	1.06 (0.10 to 2.23; p=0.074)	10 (5 to 72)
All-cause mortality	4.82 (1.48 to 8.15; p=0.0047)	1.44 (0.20 to 2.68; p=0.023)*	10 (6 to 25)




Morbidity and mortality after lifestyle intervention in people with IGT: The Da Qing Study 30-year follow-up





Long-term effects of lifestyle intervention on weight & CVD risk in type 2 diabetes: the Look AHEAD trial



Magnitude of change weight loss and change in fitness and CVD outcomes in the Look AHEAD trial

	Weight-change categories (percentage weight loss in first year; n=4834)					Fitness-change categories (change in metabolic equivalents in first year; n=4406)				
	Gain or stable (<2% loss)	Small loss (≥2-<5%)	Medium loss (≥5-<10%)	Large loss (≥10%)	p value	Loss or stable (<0.5 loss)	Small gain (≥0.5-<1.0)	Medium gain (≥1.0-<2.0)	Large gain (≥2.0)	p value
Primary outcome										
Events per person-years	289/17 075	141/7870	154/857	128/8942	..	347/19 997	95/6091	102/7183	72/5312	..
Crude rate per 100 person-years	1.69	1.79	1.80	1.42	..	1.74	1.56	1.42	1.36	..
Unadjusted hazard ratio (95% CI)	1.00	1.07 (0.88-1.31)	1.07 (0.88-1.31)	0.83 (0.67-1.02)	0.21	1.00	0.88 (0.70-1.10)	0.80 (0.64-1.00)	0.76 (0.59-0.98), p=0.022*	0.009
Adjusted hazard ratio†(95% CI)	1.00	1.08 (0.88-1.33)	1.16 (0.95-1.42)	0.79 (0.64-0.98), p=0.034*	0.17	1.00	0.87 (0.68-1.10)	0.83 (0.66-1.05)	0.78 (0.60-1.03), p=0.079*	0.03
Secondary outcome										
Events per person-years	422/16 699	206/7657	203/8411	186/8792	..	504/19 596	131/5996	145/7056	100/5220	..
Crude rate per 100 person-years	2.53	2.69	2.41	2.12	..	2.57	2.18	2.05	1.92	..
Unadjusted hazard ratio (95% CI)	1.00	1.08 (0.91-1.27)	0.96 (0.81-1.13)	0.83 (0.70-0.99), p=0.035*	0.04	1.00	0.83 (0.69-1.01)	0.79 (0.65-0.95), p=0.012*	0.73 (0.59-0.91), p=0.005*	0.0005
Adjusted hazard ratio† (95% CI)	1.00	1.05 (0.88-1.25)	0.97 (0.82-1.16)	0.76 (0.63-0.91), p=0.003*	0.006	1.00	0.84 (0.69-1.02)	0.79 (0.65-0.96), p=0.019*	0.77 (0.61-0.96), p=0.023*	0.0031


Data are for the overall study population (intensive lifestyle intervention and diabetes support and education [control] groups combined). *p value refers to pairwise comparison with referent group (gain or stable weight loss in weight-change analyses and loss or stable fitness gain in fitness change analyses). †Adjusted for sex, age, baseline weight (from weight-change models), baseline fitness (from fitness-change models), history of cardiovascular disease, insulin use, diabetes duration, smoking status, LDL cholesterol, systolic blood pressure, and diastolic blood pressure.

Table 2: Primary and secondary outcomes associated with changes in weight and fitness (overall study population)

Key messages

Physical activity and other health outcomes

- High cardiorespiratory fitness and high muscular strength are associated with lower risk of mortality in patients with type 2 diabetes
- In Look Ahead, participants who increased cardiorespiratory fitness reduced incidence of adverse CVD outcomes
- We need to develop better interventions to help support people to sustain long-term behaviour change (years to decades)





**Can diabetes remission be achieved
through lifestyle interventions
focused on physical activity?**

U-TURN – Secondary analysis for diabetes remission at 12 and 24 months

Received: 11 April 2019 | Revised: 23 May 2019 | Accepted: 2 June 2019
DOI: 10.1111/dom.13802

ORIGINAL ARTICLE

WILEY

Type 2 diabetes remission 1 year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

Mathias Ried-Larsen PhD¹ | Mette Y. Johansen MSc¹ |
Christopher S. MacDonald MSc^{1,2} | Katrine B. Hansen PhD¹ |
Robin Christensen PhD^{3,4} | Anne-Sophie Wedell-Neergaard MD¹ |
Nanna Skytt Pilmark MD¹ | Henning Langberg DMSc² | Allan A. Vaag PhD⁵ |
Bente K. Pedersen DMSc¹ | Kristian Karstoft PhD^{1,6}

¹Centre of Inflammation and Metabolism and Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
²CopenRehab, Section of Social Medicine, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
³Musculoskeletal Statistics Unit, Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
⁴Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
⁵Cardiovascular and Metabolic Disease Translational Medicine Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
⁶Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

Correspondence

Mathias Ried-Larsen, PhD, Rigshospitalet
7641, Centre of Inflammation and Metabolism
and the Centre for Physical Activity Research,
Blegstamvej 9, Copenhagen 2100, Denmark.
Email: mathias.ried-larsen@regionh.dk

Funding information

This project was funded by TrygFonden. The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. The Centre for Inflammation and Metabolism/CFAS is a member of the Danish Centre for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grants 09-067009 and 09-075724). The Contour Next glucose monitors were provided by Bayer A/S, Copenhagen, Denmark. This work was also supported by a grant from Rigshospitalet (Mette Y. Johansen). The funders had no role in design and conduct of the study; collection, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Peer Review

The peer review history for this article is available at <https://publons.com/publon/10.1111/dom.13802>.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Diabetes Obes Metab. 2019;21:2257–2266.

wileyonlinelibrary.com/journal/dom | 2257

- 98 T2DM patients with <10 years disease duration, HbA1c ≤ 56 mmol/mol and not on insulin
- Randomised 2:1 into lifestyle intervention (n = 64) or standard care (n = 34).
All received standardised blinded target-driven medical therapy during first 12 months
- Lifestyle intervention group received:
 - 5-6 sessions/week of aerobic & strength training (30-60 mins/session) for 12 months.
 - Diet plan with energy intake restriction for first 4 months (followed by energy balance diet).
- No intervention provided after 12 months

U-TURN – Secondary analysis for diabetes remission at 12 and 24 months

Received: 11 April 2019 | Revised: 23 May 2019 | Accepted: 2 June 2019
DOI: 10.1111/dom.13802

ORIGINAL ARTICLE

WILEY

Type 2 diabetes remission 1 year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

Mathias Ried-Larsen PhD¹ | Mette Y. Johansen MSc¹ |
Christopher S. MacDonald MSc^{1,2} | Katrine B. Hansen PhD¹ |
Robin Christensen PhD^{3,4} | Anne-Sophie Wedell-Neergaard MD¹ |
Nanna Skytt Pilmær MD¹ | Henning Langberg DMSc² | Allan A. Vaag PhD⁵ |
Bente K. Pedersen DMSc¹ | Kristian Karstoft PhD^{1,6}

¹Centre of Inflammation and Metabolism and Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
²CopenRehab, Section of Social Medicine, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
³Musculoskeletal Statistics Unit, Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
⁴Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
⁵Cardiovascular and Metabolic Disease Translational Medicine Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
⁶Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

Correspondence

Mathias Ried-Larsen, PhD, Rigshospitalet
7641, Centre of Inflammation and Metabolism
and the Centre for Physical Activity Research,
Blegstamvej 9, Copenhagen 2100, Denmark.
Email: mathias.ried-larsen@regionh.dk

Funding information

This project was funded by TrygFonden. The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. The Centre for Inflammation and Metabolism/CFAS is a member of the Danish Centre for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grants 09-067009 and 09-075724). The Contour Next glucose monitors were provided by Bayer A/S, Copenhagen, Denmark. This work was also supported by a grant from Rigshospitalet (Mette Yun Johansen). The funders had no role in design and conduct of the study; collection, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Peer Review

The peer review history for this article is available at <https://publons.com/publon/10.1111/dom.13802>.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.


Diabetes Obes Metab. 2019;21:2257–2266.

wileyonlinelibrary.com/journal/dom | 2257

Body mass

Fat mass

Lean mass



U-TURN – Secondary analysis for diabetes remission at 12 and 24 months

Received: 11 April 2019 | Revised: 23 May 2019 | Accepted: 2 June 2019
DOI: 10.1111/dom.13802

ORIGINAL ARTICLE

Type 2 diabetes remission 1 year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

Mathias Ried-Larsen PhD¹ | Mette Y. Johansen MSc¹ |
Christopher S. MacDonald MSc^{1,2} | Katrine B. Hansen PhD¹ |
Robin Christensen PhD^{3,4} | Anne-Sophie Wedell-Neergaard MD¹ |
Nanna Skytt Pilmark MD¹ | Henning Langberg DMSc² | Allan A. Vaag PhD⁵ |
Bente K. Pedersen DMSc¹ | Kristian Karstoft PhD^{1,6}

¹Centre of Inflammation and Metabolism and Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
²CopenRehab, Section of Social Medicine, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
³Musculoskeletal Statistics Unit, Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
⁴Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
⁵Cardiovascular and Metabolic Disease Translational Medicine Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
⁶Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

Correspondence

Mathias Ried-Larsen, PhD, Rigshospitalet
7641, Centre of Inflammation and Metabolism
and the Centre for Physical Activity Research,
Blegstamvej 9, Copenhagen 2100, Denmark.
Email: mathias.ried-larsen@regionh.dk

Funding information

This project was funded by TrygFonden. The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. The Centre for Inflammation and Metabolism (CIM) is a member of the Danish Centre for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grants 09-067009 and 09-075724). The Contour Next glucose monitors were provided by Bayer A/S, Copenhagen, Denmark. This work was also supported by a grant from Rigshospitalet (Mette Y. Johansen). The funders had no role in design and conduct of the study; collection, analysis, and interpretation of the data; preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication.

Peer Review


The peer review history for this article is available at <https://publons.com/publon/10.1111/dom.13802>.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Diabetes Obes Metab. 2019;21:2257–2266.

DO NOT COPY

Remission Prevalence



23% of intervention group and 7% of control group achieved remission* at 12 & 24 months. Odds Ratio 4.4 (0.8-21.4), p = 0.08.

*HbA1c <48 mmol/mol with no glucose lowering medication

Received: 11 April 2019 | Revised: 23 May 2019 | Accepted: 2 June 2019
DOI: 10.1111/dom.13802

ORIGINAL ARTICLE

WILEY

Type 2 diabetes remission 1 year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

Mathias Ried-Larsen PhD¹ | Mette Y. Johansen MSc¹ |
Christopher S. MacDonald MSc^{1,2} | Katrine B. Hansen PhD¹ |
Robin Christensen PhD^{3,4} | Anne-Sophie Wedell-Neergaard MD¹ |
Nanna Skytt Pilmark MD¹ | Henning Langberg DMSc² | Allan A. Vaag PhD⁵ |
Bente K. Pedersen DMSc¹ | Kristian Karstoft PhD^{1,6}

¹Centre of Inflammation and Metabolism and Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
²CopenRehab, Section of Social Medicine, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
³Musculoskeletal Statistics Unit, Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
⁴Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
⁵Cardiovascular and Metabolic Disease Translational Medicine Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
⁶Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

Correspondence

Mathias Ried-Larsen, PhD, Rigshospitalet
7641, Centre of Inflammation and Metabolism
and the Centre for Physical Activity Research,
Blegstamvej 9, Copenhagen 2100, Denmark.
Email: mathias.ried-larsen@regionh.dk

Funding information

This project was funded by TrygFonden. The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. The Centre for Inflammation and Metabolism/CFAS is a member of the Danish Centre for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grants 09-067009 and 09-075724). The Contour Next glucose monitors were provided by Bayer A/S, Copenhagen, Denmark. This work was also supported by a grant from Rigshospitalet (Mette Y. Johansen). The funders had no role in design and conduct of the study; collection, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Peer Review

The peer review history for this article is available at <https://publons.com/publon/10.1111/dom.13802>.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. *Diabetes, Obesity and Metabolism* published by John Wiley & Sons Ltd.

Diabetes Obes Metab. 2019;21:2257–2266.

wileyonlinelibrary.com/journal/dom | 2257


Remission associated with:

- Greater reduction in fat mass
- Greater reduction in abdominal fat mass
- Achieving 10% body weight reduction
- Greater increases in cardiorespiratory fitness

Key messages

Physical activity, weight and glycaemic control

- With an intense enough exercise-focused intervention, substantial weight loss is possible, leading to diabetes remission in some
- This approach may be appealing to some (probably a minority) of patients with type 2 diabetes





Device-measured VILPA and risk of mortality

nature medicine

Article

Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality

Received: 3 March 2022

Accepted: 21 October 2022

Published online: 8 December 2022

[Check for updates](#)

Emmanuel Stamatakis¹, Matthew N. Ahmadi¹, Jason M. R. Gill², Cecilie Thøgersen-Ntoumani³, Martin J. Gibala⁴, Aiden Doherty⁵ & Mark Hamer⁶

Wearable devices can capture unexplored movement patterns such as brief bursts of vigorous intermittent lifestyle physical activity (VILPA) that is embedded into everyday life, rather than being done as leisure time exercise. Here, we examined the association of VILPA with all-cause, cardiovascular disease (CVD) and cancer mortality in 25,241 nonexercisers (mean age 61.8 years, 14,178 women/11,063 men) in the UK Biobank. Over an average follow-up of 6.9 years, during which 852 deaths occurred, VILPA was inversely associated with all three of these outcomes in a near-linear fashion. Compared with participants who engaged in no VILPA, participants who engaged in VILPA at the sample median VILPA frequency of 3 length-standardized bouts per day (lasting 1 or 2 min each) showed a 38%–40% reduction in all-cause and cancer mortality risk and a 48%–49% reduction in CVD mortality risk. Moreover, the sample median VILPA duration of 4.4 min per day was associated with a 26%–30% reduction in all-cause and cancer mortality risk and a 32%–34% reduction in CVD mortality risk. We obtained similar results when repeating the above analyses for vigorous physical activity (VPA) in 62,344 UK Biobank participants who exercised (1,552 deaths, 35,290 women/27,054 men). These results indicate that small amounts of vigorous nonexercise physical activity are associated with substantially lower mortality. VILPA in nonexercisers appears to elicit similar effects to VPA in exercisers, suggesting that VILPA may be a suitable physical activity target, especially in people not able or willing to exercise.

Physical activity is associated with reduced mortality risk¹, and reduced risk of CVD² and certain cancers^{3–5}. Recently updated guidelines^{6,7}, based mostly on questionnaire-derived evidence, recommend 150–300 min of moderate-intensity activity or 75–150 min of vigorous-intensity physical activity (≥6 metabolic equivalents) per week. New emphasis is placed on ‘all activity counts’ occurring across all life domains and regardless of bout duration. This recommendation contrasts with previous guidelines⁸ that did not recognize the health value of physical activity bouts

¹Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. ²School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. ³Danish Centre for Motivation and Behaviour Science, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark. ⁴Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada. ⁵Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. ⁶Institute Sport Exercise Health, Division Surgery Interventional Science, University College London, London, UK. ✉e-mail: emmanuel.stamatakis@sydney.edu.au

Nature Medicine | Volume 28 | December 2022 | 2521–2529

2521

